A Novel N-ras Mutation in Malignant Melanoma Is Associated with Excellent Prognosis

Anouk Demunter, Mohammad Reza Ahmadian, Louis Libbrecht, Marguerite Stas, Mathijs Baens, Klaus Scheffzek, Hugo Degreve, Chris De Wolf-Peeters, and Joost J. van den Oord

Laboratory of Morphology and Molecular Pathology, Departments of Pathology [A. D., L. L., C. D. W.-P., J. v. d. O.], Surgical Oncology [M. S.], and Dermatology [H. D.], Katholieke Universiteit Leuven, Leuven 3000, Belgium; Human Genome Laboratory, Center for Human Genetics, Flanders Interuniversity Institute for Biotechnology, Leuven 3000, Belgium [M. R.]; Max-Planck Institute, Dortmund 44227, Germany [M. R. A.]; and European Molecular Biology Laboratory, Heidelberg 69120, Germany [K. S.]

ABSTRACT

Mutations in the ras gene are key events in the process of carcinogenesis; in particular, point mutations in codon 61 of exon 2 of the N-ras gene occur frequently in malignant melanoma (MM). We searched for point mutations in the N-ras gene in a large series of primary and metastatic MM from 81 different retrospectively selected patients using the very sensitive denaturing gradient gel electrophoresis technique, followed by sequencing. The classical codon 12 and codon 61 mutations were found in 21 and 17% of the cases, respectively. No codon 13 mutation was found. A novel mutation at codon 18 of exon 1, consisting of a substitution of alanine (GCA) by threonine (ACA), was found in 15% of the primary MMs but in none of the metastatic MMs. All of the other cases were free of mutations. Using microdissected cells from distinctive MM growth phases as source of DNA for mutation analysis, this particular N-ras exon 1 mutation at codon 18 was already present in the radial growth phase and preserved throughout the successive growth phases; it was also found in a dysplastic nevus in continuity with a MM, indicating a clonal relationship between both lesions. Our findings also illustrate the clonal relationship between the distinctive growth phases in MM and suggest the codon 18 mutation to occur early in MM development. The MM in patients with this mutation were significantly thinner than those without a codon 18 mutation (P = 0.0257). Statistical analysis, comparing the group of codon 18 patients with the group of patients with the classical mutations and without mutations, revealed a highly significant difference in overall outcome. The cumulative probability of developing metastasis was significantly lower for the group patients with a codon 18 mutation (P = 0.0130). We can thus conclude that this codon 18 mutation identifies a group of patients with better prognosis than patients with melanoma that harbor wild-type sequence or classical activating point mutations in codon 12 or 61.

Preliminary nucleotide binding measurements could not detect a difference between wild-type Ras protein and the mutant Ras(A18T) protein. However, for a precise elucidation of the role of the N-Ras(A18T) mutant in melanoma, additional studies aimed to measure the affinity to guanine nucleotide exchange factors and GTPase-activating proteins are needed.

INTRODUCTION

Most malignant tumors are characterized by the occurrence of multiple mutations throughout the genome, which will alter the products of a number of genes, controlling cell growth and differentiation. These mutations will accumulate in a step-wise manner during tumor progression. Mutations in many different genes have been described in MM1 including the ras genes. This family consists of three functional oncogenes, H-ras, K-ras, and N-ras, which encode highly similar proteins with molecular weights of Mr 21,000 (1). Normal p21 Ras proteins, showing structural and functional resemblance with the G-proteins (controlling adenylate cyclase) are involved in the transduction of external stimuli, induced by the binding of growth factors or factors involved in cell differentiation to a specific receptor such as receptor tyrosine kinase. Activated Ras proteins have been shown to interact with numerous downstream targets, to activate several different signaling pathways, and subsequently become inactivated (2, 3). Mutated Ras proteins, however, have lost the ability to become inactivated and thus stimulate cellular growth and differentiation continuously (3). Experimental evidence indicates that inhibition of their GTPase activity is the preferred mechanism of activation of oncogenic Ras proteins (4–6).

Mutations in naturally occurring ras oncogenes have been found in codons 11, 12, 13, 59, and 61 (7–11). In MM, mutations in ras oncogenes have repeatedly been detected, although their role in the pathogenesis of MM still remains poorly understood. Using cultured melanoma cells, Albino et al. (12) found mutations in 24% of the cases, in contrast to 5–6% of the noncultured primary and metastatic MMs. Using mutation-specific oligonucleotide hybridization, van’t Veer et al. (13) detected N-ras mutations in 7 of 37 (19%) melanoma tumor samples from sun-exposed body sites, and Ball et al. (14) investigated 100 paraffin-embedded primary and metastatic MMs using dot blot hybridization and found a mutation frequency of 36%. In all of these studies, the overwhelming majority of mutations were located in codon 61 of N-ras exon 2, attributable to the preferential formation of cyclobutane dimers at this site after UV irradiation (15).

Thus far, the activating ras mutations have not been localized to distinctive growth phases of MM, and hence, it is as yet unknown whether they are involved in early or late stages of tumor progression. We have studied the occurrence of N-ras mutations in the distinctive tumor progression stages of MM using microdissected cells, isolated from distinctive growth phases, as a source of DNA for mutation analysis. During this study, we have found a novel mutation in codon 18 of N-ras exon 1, which will be the subject of this report. To determine the clinical and biological significance of this mutation, we evaluated clinical and histological data of the patients and introduced this mutation into H-ras to reveal the biochemical properties of the mutant protein.

MATERIALS AND METHODS

Cell Lines. N-ras transfectants 11A15 and 7D8 and melanoma cell line Mel-634 were kindly provided by C. Aarnoudse (Department of Clinical Oncology, University Hospital, Leiden, the Netherlands; Ref. 16). The MOLT-4 cell line was provided by J. Van Pel (Laboratory of Hapatology, University Hospitals Leuven, Leuven, Belgium; Ref. 17).

Patient Material. Sixty-nine primary MMs and 33 melanoma metastases from 81 different patients were used for this study. These cases were randomly

β-y-imidophosphoribosyl; mGppNHp, mutant GppNHp; SSCP, single-strand conformation polymorphism; GAF, GTPase-activating protein; GEF, guanine nucleotide exchange factor; TIL, tumor-infiltrating lymphocyte.

Received 1/10/01; accepted 4/11/01.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 Supported in part by Grant OT98/33 from the Katholieke Universiteit Leuven (to A. D.).

2 To whom requests for reprints should be addressed, at Department of Pathology, Laboratory of Morphology and Molecular Pathology, University Hospital S. Rafael, Minderbroederstraat 12, 3000 Leuven, Belgium, Phone: 32-16-33-66-44; Fax: 32-16-33-65-48; E-mail: anouk.dumenter@uz.kuleuven.ac.be.

3 The abbreviations used are: MM, malignant melanoma; RGP, radial growth phase; VGP, vertical growth phase; DGGCE, denaturing gradient gel electrophoresis; DOP-PCR, degenerated oligonucleotide-primed PCR; ncn, nevocellular nevus; GppNHp, guanosine 5′-48-48; E-mail: anouk.dumenter@uz.kuleuven.ac.be.

44916

Downloaded from cancerres.aacrjournals.org on April 30, 2017. © 2001 American Association for Cancer Research.
retrieved from the archives of the Department of Pathology starting from 1985 until 2000. From 19 patients, both the primary MMMs and the metastases were available for analysis. Seven MMMs were associated with ncn including 1 dermal ncn, 4 compound ncn, 1 lentigo simplex, 2 dysplastic ncn, and 1 congenital nevus. From 62 cases, the material was received fresh; a representative part of the material was snap frozen in liquid nitrogen-cooled isopentane and stored at −80°C until used. The other part was fixed in neutral buffered formalin, embedded in paraffin, and used for routine histology. To evaluate fixation-related artifacts, both frozen and paraffin-embedded material from 10 patients were analyzed. Of the other cases, either frozen or paraffin-embedded tissue was available for study. Metastatic MMMs were analyzed by DNA extractions from whole tissue sections if >80% of the surface was involved by neoplastic tissue; in primary MMMs and associated ncn, clusters of neoplastic cells were microdissected and used as source of DNA (see below).

Follow-Up of Patients. All cases had been treated surgically according to standard procedure, and the resection margins were negative in all cases of primary MM. Of the 69 randomly selected patients with a primary MM, 51 had been followed for at least 6 months after resection of the tumor and clinical examinations, X-ray, sonography, and analysis of serum liver enzyme levels revealed no metastasis at the time of diagnosis. These 51 cases, all stages I and II [according to the American Joint Committee on Cancer system (18)], were then used for statistical analysis in a retrospective study. The date of the histopathological diagnosis was used as the entry date. The duration of follow-up was the time (measured in months) from the diagnosis to either the detection of metastasis, the date of death attributable to a cause unrelated to the MM, or the date of the most recent control. All patients underwent regular follow-up according to a standard protocol that included clinical examinations, X-ray and sonography, and analysis of serum liver enzyme levels.

All primary MMMs were reevaluated histologically, and in each case, the classical histological prognostic criteria were assessed according to standard criteria (19). The following baseline characteristics were used in the statistical analysis: sex, age, thickness according to Breslow (<1 mm; 1.01–2.0 mm; 2.01–4.0 mm; or >4 mm), mitotic index (<6/mm² or >6/mm²), tumor infiltration by lymphocytes (TILs), ulceration, regression, vascular invasion, and mutations in codons 12, 18, and 61 of the N-ras gene. Histopathological reevaluation of all cases occurred without knowledge of the mutation status of N-ras codons 12, 18, and 61 according to standard criteria.

Microdissection. Buffered formalin-fixed, paraffin-embedded, and/or frozen sections of all primary MMMs, showing well-recognizable, distinctive tumor progression phases on histology, were subjected to microdissection. After staining with H&E, both frozen and paraffin-embedded tissue sections were digested by incubation at 40°C for 3 h in collagenase H (Boehringer Mannheim, Brussels, Belgium). Subsequently, the various tumor progression phases of the MMMs were identified, i.e., the “pure” RGP, restricted to the epidermis; the “invasive” RGP, characterized by small nonexpansile clusters or single neoplastic cells in the papillary dermis; the VGP, consisting of expansile cohesive nodules of neoplastic cells in the dermis, and/or the metastatic phase. Depending on the tumor-progression phase, 20–100 cells were collected per cohesive nodule of neoplastic cells in the dermis, and/or the metastatic phase. The cells were aspirated with another sterile glass needle, transferred to an Eppendorf tube, and resuspended in 5 µl of 5 mM nucleotide-free Ras proteins with a 1.5-fold molar excess of the fluorescent nucleotide triphosphate, 0.2 mM MgCl₂, 200 µM each deoxynucleotide triphosphate, 0.2 µM of each primer [for N-ras exon 1: forward, 5′-CTGGTTGGAATGACTGAT-3′ and reverse, 5′-[GC]-GGTTGGATCTA- TATCATCTA-3′; for N-ras exon 2: forward, 5′-GTTATATGTTGAACCTG and reverse, 5′-ATACAGAGGAGCTTC-3′ (22)], 500 ng of DNA and 2.5 units of Taq polymerase (AmpliTaq Gold; Perkin-Elmer). A 40-bp GC-clamp was attached to the reverse primer ([GC] = CGCCCGC-CGCCGCCCGGCGCCGCGCCCCGC). The product was purified (Qiagen Westburg, Leusden, the Netherlands) before further use. DGGE. To test the DGGE conditions needed for this approach, cell lines harboring well-known mutations were analyzed, i.e., MOLT4 (heterozygous for mutation in N-ras codon 12 position 1), N-ras transfectants 11A15 (L1-81-L1 (61-Leu)/) and 7D8 [MD3A-K (61-Lys/K)], and the melanoma cell line Mel-634 (with a natural arginine mutation in codon 61 of N-ras). A 12% polyacrylamide gel containing a gradient of urea and formamide from 20 to 50% was sufficient to detect all of the cell line mutations. To demonstrate the sensitivity of the DGGE assay, the mutant PCR product was mixed with the corresponding wild-type PCR product to generate heteroduplexes, i.e., hybrids formed between mutant and wild-type DNA strands (Fig. 1A). DNA from MOLT-4 cell line (heterozygous for mutation in N-ras codon 12 position 1) was serially diluted with normal human spleen and revealed a detection sensitivity of 2.5% mutant DNA in wild-type sample (Fig. 1B).

Forty µl of PCR product was dried out and loaded on the gels to run at 170 V for 4 h in 1× TAE buffer (40 mM Tris, 20 mM acetic acid, and 1 mM EDTA, pH 8.3), kept at a constant temperature of 60°C. DNA sequencing was done to confirm the results on the DGGE gel.

Biochemical Characterization of the Mutant Protein and Nucleotide Affinity. Recombinant H-Ras (A18T) protein was prepared from Escherichia coli using the ptc expression system as described (23). The nucleotide-free form of this mutant was prepared as described for H-Ras (24). The fluorescent derivatives of GDP (guanosine 5′-diphosphate) and GppNHp (a nonhydrolyzable GTP analogue), mGDP, and mGppNHp were synthesized as described (24). Ras(A18T)mGDP and Ras(A18T)mGppNHp were prepared by loading nucleotide-free Ras proteins with a 1.5-fold molar excess of the fluorescent nucleotide. Excess nucleotide was separated from nucleotide-bound Ras by gel filtration on prepacked NAP-5 columns (Pharmacia, Uppsala, Sweden). Nucleotide-bound Ras(A18T) concentration was determined by high-performance liquid chromatography on a C18 reversed phase column (Bishoff, Leonberg) as described (23). All fluorescence measurements were performed using an excitation wavelength of 366 nm and an emission wavelength of 450 nm in 30 mM Tris/HCl (pH 7.5), 10 mM MgCl₂, 3 mM dioxygenethanol at 25°C. The nucleotide dissociation kinetics of 0.1 µM mGDP and mGppNHp-bound Ras(A18T) in the presence of 50 µM nonlabeled GDP/GppNHp were performed on a LS50B Perkin-Elmer spectrofluorometer as described (25). The fitted curve was obtained using a single exponential equation using the program Grafit (Erithacus software).

The nucleotide association kinetics were measured by mixing 1 µM nucleotide with 0.5 µM wild-type protein (5–6) and 0.1 µM mutant protein. The dissociation from the complexes was measured by collecting data every 10 s.

Fig. 1. Sensitivity of the DGGE mutation detection assay. A. To demonstrate the sensitivity of the DGGE, a mutant sample (Lanes 2, codon 18 mutation) was mixed with a wild-type sample (Lanes 3) to generate heteroduplexes (Lanes 4). Mutations were clearly resolved by showing a band pattern deviant from that of the wild type. B. DNA from the MOLT-4 cell line (heterozygous for mutation in N-ras codon 12 position 1) was serially diluted with normal human spleen and revealed a detection sensitivity of 2.5% mutant DNA in wild-type DNA. Lanes 1–9 represent the dilution of the MOLT-4 cell line (100, 80, 60, 40, 20, 10, 5, 2.5, and 0% in Lane 9). Lane 10, a wild-type pattern of a wild-type sample.
otide free form of Ras(Ala18T) with increasing amounts of mGDP and mGppNHp on a Applied Photophysics SX16 MV stopped-flow apparatus as described (25). The observed rate constants were obtained from single (mGDP) and double (for mGppNHp) exponential curves fitted to data. According to a two-step binding model, a hyperbolic curve was fitted to the observed rate constants plotted against the nucleotide concentration.

**Statistical Analysis.** Baseline characteristics were compared using Fisher’s exact test or the Mann Whitney test, when appropriate. Quantitative data were expressed as mean ± SD. The end point of the retrospective study was the occurrence of metastasis. Patients without evidence of metastasis were censored at the date of the most recent control or the date of death attributable to a cause unrelated to MM. The Kaplan-Meier method was used to reflect actual metastasis occurrence (26). Distributions of the occurrence of metastasis were compared for each baseline characteristic with the log-rank test (27). For all tests, significance was accepted when $P < 0.05$. Statistical analysis was performed using Statview 5.0.1 (SAS Institute) on a Power Macintosh.

**RESULTS**

One hundred and two malignant lesions (69 primary MMs and 33 metastases) and 9 ncn were studied for mutations in exons 1 and 2 of the N-ras gene using the PCR/DGGE approach. Thirty-four (31%) samples showed bandshifts for N-ras exon 1 (Table 1). Of these, 13 primary MMs and 6 metastases revealed a codon 12 mutation; no codon 13 mutation was seen. Two primary MMs were associated with a benign nevus, i.e., a congenital compound ncn and a dysplastic ncn; in both cases, the ncn and the primary MM carried the same codon 12 mutation. Unexpectedly, 10 primary MM showed a hitherto undescribed codon 18 mutation in N-ras exon 1 (Table 1; Fig. 2) in which GCA (alanine) was mutated to ACA (threonine). This codon 18 mutation was not found in any of the metastatic MM examined. Bandshifts for N-ras exon 2 were found in 9 (13%) primary MMs, 8 (24%) metastatic MMs, and in 2 ncn, both associated with primary MMs that also exhibited N-ras exon 2 mutations.

To confirm our results and to exclude the occurrence of false-positive and -negative results attributable to formalin fixation or attributable to too small amounts of DNA, 10 cases were studied in both frozen and paraffin-embedded material, and in these 10 cases, DNA was extracted both from microdissected cells as well as from whole tissue slides. These four different approaches revealed identical results on DGGE scanning.

To determine the onset of the codon 18 mutation during tumor progression, all cases with this mutation were studied by microdissection of distinctive tumor progression stages, followed by DOP-PCR (Table 2). In 9 cases, two growth phases could be discerned and used for microdissection; in the case of lentigo maligna, only the RGP was studied. As shown in Table 2, the GCA→ACA mutation in codon 18 was already present in the RGP and preserved throughout the successive growth phases but did not occur de novo in the invasive RGP or VGP. One case showed a dysplastic nevus in continuity with a primary MM, and the codon 18 mutation was found in both the DNA, isolated from the dysplastic nevus, as well as in the DNA isolated from the tumor cells in the RGP and VGP of the adjacent MMs. The latter case, as well as a superficial spreading MM (case 1), revealed an additional mutation in codon 61 of N-ras exon 2.

To exclude the possibility of polymorphism at codon 18 of N-ras, other paraffin-embedded tissues from 3 patients harboring a codon 18 mutation in their MMs were analyzed and revealed wild-type sequences for N-ras. The histopathological baseline characteristics of the primary MMs and the correlation between codon 18 mutation status and the other baseline characteristics are shown in Table 3. The primary MMs harboring a codon 18 mutation were significantly thicker than those with a mutation in codon 12 or 61. There were no other significant correlations between codon 18 mutation status and the other baseline characteristics. There were no significant correlations between the codon 12 or codon 61 mutation status and any of the other baseline characteristics.

During the mean follow-up of 40 ± 34 months, 23 of the 51 patients (45%) developed metastasis of the primary MMs after a mean time of 23 ± 7 months. The diagnosis of melanoma metastasis was based on histopathological examination of the surgically resected metastasis. Of the 23 patients who developed metastasis, 13 died after a mean survival of 20 ± 17 months, and 10 were still alive at the time of this study and have been followed for a mean of 14 ± 6 months. Of the 28 patients who did not develop metastasis, 2 patients died of a cause unrelated to MM (non-Hodgkin’s lymphoma and pneumonia). The cumulative probability of developing metastasis was significantly higher for patients whose primary MMs were thicker, had no mutation of codon 18, or showed vascular invasion (Table 4; Fig. 3).

After exclusion of the 16 patients who had a mutation in codons 12 and/or 61 of N-ras, the study population was reduced to 35 melanoma patients, of whom 8 (23%) had a mutation in codon 18, and all of the other were free of mutations. The mean follow-up of this group was 44 ± 34 months, and 15 of these 35 patients (43%) developed metastatic disease after a mean time of 23 ± 16 months. There was no significant correlation between codon 18 mutation status on the one hand and the other baseline characteristics. The cumulative probability of developing metastasis for this group was also significantly higher for male patients and for patients whose primary MMs were thicker, had no mutation of codon 18, or showed vascular invasion ($P = 0.0159; P = 0.0027; P < 0.0227; P < 0.0001$ respectively; data not shown).

To study the biochemical consequences of the GCA→ACA codon 18 mutation, H-Ras(Ala18T) was expressed in Escherichia coli, and the mutant protein was isolated at high purity. Although less stable than wild type, we were able to isolate this mutant protein in a nucleotide-free form, which was then used to determine the nucleotide binding properties. Dissociation and association rate constants were 2- and 5 times greater for the mutant compared to the wild type form of Ras(Ala18T) expressed in the MOLT-4 cell line (het-eryogenous for mutation in N-ras codon 12 position 1, Lane 2) and two unknown samples (Lanes 3 and 4). Both unknown samples carry the codon 18 mutation (alanine to threonine) in N-ras exon 1.

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>Wild type</th>
<th>Cod. 12&lt;sup&gt;a&lt;/sup&gt; mut</th>
<th>Cod. 18&lt;sup&gt;a&lt;/sup&gt; mut</th>
<th>Cod. 61&lt;sup&gt;a&lt;/sup&gt; mut</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common acq. nevi</td>
<td>6</td>
<td>5</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Congenital nevi</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Dysplastic nevi</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Clark I and LM</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Clark II</td>
<td>7</td>
<td>6</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Clark III</td>
<td>15</td>
<td>8</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>Clark IV</td>
<td>37</td>
<td>24</td>
<td>9</td>
<td>7</td>
</tr>
<tr>
<td>Clark V</td>
<td>8</td>
<td>7</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Metastases</td>
<td>21</td>
<td>23</td>
<td>6</td>
<td>8</td>
</tr>
<tr>
<td>Total</td>
<td>111</td>
<td>73 (66%)</td>
<td>23 (21%)</td>
<td>11 (10%)</td>
</tr>
</tbody>
</table>

<sup>a</sup> Mutations (mut) are seen in codon (Cod.) 12 and 18 of N-ras exon 1 and in codon 61 of N-ras exon 2.

<sup>b</sup> Common acquired (acq) nevi: 1 dermal nevus; 1 lentigo benigna; 4 compound nevi.

**Table 1 Results of DGGE mutation screening**

![Fig. 2. Identification of mutations in exon 1 of the N-ras gene by DGGE analysis.](image-url)
sensitive enough to distinguish between wild-type and mutated alleles (9, 19, 30). RFLP assays are normally limited to the detection, in each setting, of a base change at only two positions in one codon of a ras gene or even to the detection of only one specific ras mutation (31, 32). SSCP and DGGE are now the two major techniques in mutation scanning. SSCP is less sensitive than DGGE and is more dependent on the length of the fragment (33).

Sensitivity of mutation detection by SSCP falls dramatically with increasing length of the analyzed fragment. To overcome these problems, we have chosen for the DGGE technique to study mutations in N-ras exons 1 and 2 in a large series of MM. To the best of our knowledge, this is the first time that DGGE scanning is used to detect N-ras gene mutations in MM.

Analyzing N-ras mutations in a large group of MM, we could distinguish three groups of patients, i.e., a group without mutations, a group with the classical activating point mutations in codons 12 and 61, and a group of patients with a novel point mutation in codon 18 of N-ras exon 1. The latter mutation occurred in 10 of 102 (10%) malignant pigment cell lesions and resulted in a substitution of alanine (GCA) by threonine (ACA). This mutation was found in tumor DNA of two patients, a 65-year-old man and a 67-year-old woman, whose clinical characteristics were similar to those of the other patients in the study.

Several techniques have been used to analyze ras gene mutations in human tumors. NIH 3T3 transfection assays using either in vitro or in vivo selection are laborious and time consuming and may introduce selection artifacts (28, 29). Hybridization techniques would miss any exon 1 and 2 mutations other than those targeted by the specific probes chosen for the assay and are often not sensitive enough to distinguish between wild-type and mutated alleles (9, 19, 30). RFLP assays are normally limited to the detection, in each setting, of a base change at only two positions in one codon of a ras gene or even to the detection of only one specific ras mutation (31, 32). SSCP and DGGE are now the two major techniques in mutation scanning. SSCP is less sensitive than DGGE and is more dependent on the length of the fragment (33).

DISCUSSION

Several techniques have been used to analyze ras gene mutations in human tumors. NIH 3T3 transfection assays using either in vitro or in vivo selection are laborious and time consuming and may introduce selection artifacts (28, 29). Hybridization techniques would miss any exon 1 and 2 mutations other than those targeted by the specific probes chosen for the assay and are often not sensitive enough to distinguish between wild-type and mutated alleles (9, 19, 30). RFLP assays are normally limited to the detection, in each setting, of a base change at only two positions in one codon of a ras gene or even to the detection of only one specific ras mutation (31, 32). SSCP and DGGE are now the two major techniques in mutation scanning. SSCP is less sensitive than DGGE and is more dependent on the length of the fragment (33).

Sensitivity of mutation detection by SSCP falls dramatically with increasing length of the analyzed fragment. To overcome these problems, we have chosen for the DGGE technique to study mutations in N-ras exons 1 and 2 in a large series of MM. To the best of our knowledge, this is the first time that DGGE scanning is used to detect N-ras gene mutations in MM.

Analyzing N-ras mutations in a large group of MM, we could distinguish three groups of patients, i.e., a group without mutations, a group with the classical activating point mutations in codons 12 and 61, and a group of patients with a novel point mutation in codon 18 of N-ras exon 1. The latter mutation occurred in 10 of 102 (10%) malignant pigment cell lesions and resulted in a substitution of alanine (GCA) by threonine (ACA). This mutation was found in tumor DNA derived from both frozen and formalin-fixed tissue section, and the same results were obtained when DNA was extracted from whole tissue sections (immediately used for specific PCR), as well as when DNA was obtained from small numbers of cells (microdissected from distinctive stages of tumor progression in frozen or paraffin-embed-
Table 3 Clinical and histopathological baseline characteristics and their correlation with codon 18 mutation status

| Baseline characteristic | All patients n (%) | Patients without codon 18 mutation n (%) | Patients with codon 18 mutation n (%) | P
|-------------------------|--------------------|----------------------------------------|--------------------------------------|---
| Age                     | 51 (19)            | 41 (19)                                | 10 (20)                              | 0.8125
| Sex                     | 67 (19)            | 68 (20)                                | 66 (20)                              | 0.125
| Male                    | 24 (47)            | 20 (40)                                | 4 (40)                               | 0.4190
| Female                  | 27 (53)            | 21 (51)                                | 6 (60)                               | 0.2928
| Breslow                 | 2.85 ± 3.30        | 3.21 ± 3.65                            | 1.37 ± 0.38                          | 0.0257
| ≤2 mm                   | 23 (45)            | 15 (36)                                | 8 (80)                               | 0.0990
| >2 mm                   | 28 (55)            | 26 (64)                                | 2 (20)                               | 0.4921
| Mitotic index ≤6/mm²    | 41 (80)            | 33 (80)                                | 8 (80)                               | 0.571
| >6/mm²                  | 10 (20)            | 8 (20)                                 | 2 (20)                               | 0.4921
| TIL                     | Absent             | 30 (59)                                | 23 (56)                              | 0.4853
| Present                 | 21 (41)            | 18 (44)                                | 3 (30)                               | 0.2952
| Ulceration              | Absent             | 24 (47)                                | 18 (44)                              | 0.4190
| Present                 | 27 (53)            | 23 (66)                                | 4 (40)                               | 0.9990
| Regression              | Absent             | 29 (57)                                | 25 (61)                              | 0.4190
| Present                 | 22 (43)            | 16 (39)                                | 6 (60)                               | 0.2499
| Vascular invasion       | Absent             | 38 (75)                                | 29 (71)                              | 0.0920
| Present                 | 13 (25)            | 12 (29)                                | 1 (10)                               | 0.0130
| Codon 12 mutation       | Absent             | 39 (77)                                | 29 (77)                              | 0.7783
| Present                 | 12 (25)            | 12 (25)                                | 0 (0)                                | 0.5571
| Codon 61 mutation       | Absent             | 22 (43)                                | 12 (29)                              | 0.2773
| Present                 | 5 (10)             | 3 (10)                                 | 2 (20)                               | 0.3368

* Values in parentheses are column percentages.

† Fisher’s exact test or Mann-Whitney test.

Table 4 Clinical and histopathological baseline characteristics in relation to the occurrence of metastasis

| Codon 18 mutation | Patients with metastasis n (%) | P
|-------------------|-------------------------------|---
| Codon 18 mutation |                               |   |
| Absent            | 41 (22)                       | 0.0130
| Present           | 10 (10)                       |   |
| Codon 12 mutation |                               |   |
| Absent            | 39 (17)                       | 0.4921
| Present           | 12 (60)                       |   |
| Codon 61 mutation |                               |   |
| Absent            | 46 (20)                       | 0.5571
| Present           | 5 (10)                        |   |
| Breslow           |                               |   |
| ≤1.0 mm           | 10 (20)                       | 0.0115
| 1.01–2.0 mm       | 12 (35)                       |   |
| 2.01–4.0 mm       | 22 (52)                       |   |
| >4.0 mm           | 7 (15)                        |   |
| Age               |                               |   |
| ≤55 years         | 12 (5)                        | 0.7783
| >55 years         | 39 (19)                       |   |
| Sex               |                               |   |
| Male              | 24 (14)                       | 0.0568
| Female            | 27 (9)                        |   |
| Mitotic index     |                               |   |
| ≤6/mm²            | 41 (18)                       | 0.4785
| >6/mm²            | 10 (5)                        |   |
| TIL               |                               |   |
| Absent            | 30 (12)                       | 0.2773
| Present           | 21 (11)                       |   |
| Ulceration        |                               |   |
| Absent            | 24 (8)                        | 0.1881
| Present           | 27 (55)                       |   |
| Regression        |                               |   |
| Absent            | 29 (15)                       | 0.2528
| Present           | 22 (8)                        |   |
| Vascular invasion |                               |   |
| Absent            | 38 (13)                       | 0.0006
| Present           | 13 (7)                        |   |

* Values in parentheses are row percentages.

† Log-rank test.

Fig. 3. Cumulative probability of remaining free of metastasis for patients with and without codon 18 mutation. Statistical analysis was done on a group of 51 patients that had been followed for at least 6 months after resection of the tumor. The end point of the retrospective study was the occurrence of metastasis. The Kaplan-Meier method was used as described in “Materials and Methods.” The cumulative probability of developing metastasis was significantly lower for the group of patients with a codon 18 mutation in their MMs (P = 0.0130).

Accepted that dysplastic nevi are markers to identify patients who are at increased risk to develop MM, there is much debate as to whether these dysplastic nevi actually serve as precursors of MM. Our demonstration of identical N-ras mutations at two different codons of N-ras in the DNA of both the dysplastic nevus as well as the adjacent MM strongly suggests a clonal relationship between both lesions.

The clinical follow-up of the patients with codon 18 mutation indicates an excellent prognosis as compared with patients with a MM harboring classical activating point mutations in codons 12 or 61 or...
with wild-type MM samples. The only patient with an N-ras codon 18 mutation that died of melanoma also carried an activating point mutation in codon 61. This excellent prognosis is likely to be attributable to the fact that MM with N-ras codon 18 mutations were significantly thinner than MM carrying activating mutations at codons 12 and 61. The fact that codon 18 mutation status correlated only with the thickness of the primary MM and not with the other clinical and histopathological characteristics strongly suggest that there exists a causal relation between both parameters. In addition, when the group of codon 18 patients was compared with the group of patients with the classical mutations as well as with those without mutations, a highly significant difference in overall outcome was found, suggesting that patients with this novel mutation are favored over those without genetic aberrations in the N-ras gene.

Our clinical and histological data therefore suggest that this novel GCA→ACA mutation in codon 18 of N-ras exon 1 interferes with the Ras-dependent mitogenic signaling pathway, resulting in slower growth and hence, earlier detection. As such, screening of MM patients for mutations in codon 18 of N-ras exon 1 may identify a subgroup of patients with a better prognosis. Future studies on prospectively followed patients are currently under way.

The precise effect of this novel N-ras codon 18 mutation on the proliferation of melanoma cells in the earliest stages of tumor progression requires extensive functional assays. However, we can make some speculations, based on the biochemical properties of the Ras protein. Alanine 18 is placed at the COOH-terminal end of the highly conserved phosphate-binding motif (GXXXGKS/TA). Amino acid substitutions within this region often impair the nucleotide binding (serine 17 mutation) and GTPase reaction (glycine 12/13 mutations). More than 30% of human tumors contain a Ras protein with point mutations mainly at codons 12 and 61, more rarely at codon 13 (2).

Ras proteins with these somatic mutations have a defective GTPase activity and can no longer be switched off by GAPs. The reason behind these dramatic functional changes by codon 12 and 13 mutation of ras are rearrangements around the active site, resulting in displacement of catalytic amino acids such as glutamine 61 of Ras and the arginine finger of RasGAP (37, 38). Unlike these oncogenic mutants, replacement of serine 17 by an asparagine dramatically affects the nucleotide binding. This mutant binds with high affinity to the Ras-specific GEFs and thereby blocks the GEF activity in cells (39, 40).

Preliminary functional studies, aimed to detect similar nucleotide binding alterations as described for mutations in codon 17, were performed. They showed a faster dissociation rate of the codon 18 mutant Ras protein from the guanine nucleotide binding site as compared with the wild-type Ras protein. However, because of faster association, the overall affinity is only marginally affected. It is interesting to note that the homologous residue in many other GTP binding proteins is threonine or serine/cysteine (41). In the structures known, polar interactions of the side chain hydroxyl groups with α-phosphate oxygen atoms were observed (e.g., EF-Tu, Ran, and others), suggesting stabilization of binding. In Ras, the structure would seemingly allow similar interactions in Ras(A18T). The GDP dissociation of N-Ras (1.0 × 10^8 s^-1) is similar to that of H-Ras (Table 5; Ref. 42). Because N-Ras and H-Ras are very similar (85% identity), differing mainly in regions not involved in nucleotide interaction, we assume that the biochemical data obtained for H-Ras(A18T) can be assigned for N-Ras(A18T) mutants. Thus, in view of these preliminary findings, additional studies aimed to measure the affinity to GEFs and GAPs are needed to elucidate the role of the N-Ras(A18T) mutant in MM.

In summary, using the very sensitive DGGE approach, we have detected a novel mutation in codon 18 of N-ras exon 1 in 15% of the primary MMs. This mutation occurs already in the earliest stages of the tumor and seems to identify a group of melanoma patients with better prognosis than those with wild-type sequence or the classical activating point mutations in codons 12 and 61. Multivariate analysis on larger groups of patients in a prospective study should, however, be performed to elucidate the prognostic value of this codon 18 mutation.

ACKNOWLEDGMENTS

We thank Miet Vanherck and Monique Pattou for assistance in the molecular pathology lab. We also thank Dorothee Kühlmann for preparing Ras(A18T) mutant.

REFERENCES

A Novel N-ras Mutation in Malignant Melanoma Is Associated with Excellent Prognosis

Anouk Demunter, Mohammad Reza Ahmadian, Louis Libbrecht, et al.


Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/61/12/4916

Cited articles
This article cites 40 articles, 11 of which you can access for free at:
http://cancerres.aacrjournals.org/content/61/12/4916.full.html#ref-list-1

Citing articles
This article has been cited by 12 HighWire-hosted articles. Access the articles at:
/content/61/12/4916.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.